{
    "clinical_study": {
        "@rank": "4765", 
        "arm_group": [
            {
                "arm_group_label": "Pelubiprofen 30 mg", 
                "arm_group_type": "Experimental", 
                "description": "Pelubiprofen 30 mg, tid"
            }, 
            {
                "arm_group_label": "Celebrex 200 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Celebrex 200 mg, tid"
            }
        ], 
        "brief_summary": {
            "textblock": "A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap.\n      for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients"
        }, 
        "brief_title": "Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients", 
        "completion_date": {
            "#text": "October 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pelubiprofen", 
            "Celebrex", 
            "Rheumatoid Arthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult males/Females aged 18~80 years\n\n          2. Patient who are taking NSAIDs for the treatment of rheumatoid arthritis\n\n          3. Patients who belong to ACR functional class 1, 2, 3\n\n        Exclusion Criteria:\n\n          1. Patients who belong to ACR functional class 4\n\n          2. Patients who are hypersensitive to clinical trial medicines or excipient\n\n          3. Patients who have experience of Cerebrovascular bleeding, bleeding disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781702", 
            "org_study_id": "DW Plb RA301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pelubiprofen 30 mg", 
                "intervention_name": "Pelubiprofen 30 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Celebrex 200 mg", 
                "intervention_name": "Celebrex 200 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Celecoxib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 7, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Changes in '100 mm pain VAS' value from baseline", 
            "safety_issue": "No", 
            "time_frame": "-14, 0, 14, 28, 42 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781702"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Daewon Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daewon Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}